These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 36344514)

  • 21. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.
    Haddad D; Nakamura K
    FEBS Lett; 2015 Dec; 589(24 Pt A):3702-13. PubMed ID: 26526613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.
    Ben-Shachar D
    J Neural Transm (Vienna); 2020 Feb; 127(2):159-168. PubMed ID: 31848775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia.
    Avissar S; Roitman G; Schreiber G
    Cell Mol Neurobiol; 2001 Dec; 21(6):799-811. PubMed ID: 12043849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple dopamine receptors and behavior.
    Joyce JN
    Neurosci Biobehav Rev; 1983; 7(2):227-56. PubMed ID: 6136014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine.
    Ben-Shachar D
    J Neurochem; 2002 Dec; 83(6):1241-51. PubMed ID: 12472879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
    Khan FH; Sen T; Maiti AK; Jana S; Chatterjee U; Chakrabarti S
    Biochim Biophys Acta; 2005 Jun; 1741(1-2):65-74. PubMed ID: 15925494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple herbal extract DA-9805 exerts a neuroprotective effect via amelioration of mitochondrial damage in experimental models of Parkinson's disease.
    Jeong JS; Piao Y; Kang S; Son M; Kang YC; Du XF; Ryu J; Cho YW; Jiang HH; Oh MS; Hong SP; Oh YJ; Pak YK
    Sci Rep; 2018 Oct; 8(1):15953. PubMed ID: 30374025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.
    Bonoldi I; Howes OD
    CNS Drugs; 2014 Jul; 28(7):649-63. PubMed ID: 24919790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
    Pirooznia SK; Yuan C; Khan MR; Karuppagounder SS; Wang L; Xiong Y; Kang SU; Lee Y; Dawson VL; Dawson TM
    Mol Neurodegener; 2020 Mar; 15(1):17. PubMed ID: 32138754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.
    Chaturvedi RK; Beal MF
    Mol Cell Neurosci; 2013 Jul; 55():101-14. PubMed ID: 23220289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.
    Akundi RS; Huang Z; Eason J; Pandya JD; Zhi L; Cass WA; Sullivan PG; Büeler H
    PLoS One; 2011 Jan; 6(1):e16038. PubMed ID: 21249202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroanatomical phenotyping in the mouse: the dopaminergic system.
    Zeiss CJ
    Vet Pathol; 2005 Nov; 42(6):753-73. PubMed ID: 16301571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease.
    Pickrell AM; Pinto M; Hida A; Moraes CT
    J Neurosci; 2011 Nov; 31(48):17649-58. PubMed ID: 22131425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress, mitochondrial respiration, and Parkinson's disease.
    Cohen G
    Ann N Y Acad Sci; 2000; 899():112-20. PubMed ID: 10863533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Dopaminergic Functions in Drosophila.
    Inoshita T; Takemoto D; Imai Y
    Methods Mol Biol; 2021; 2322():185-193. PubMed ID: 34043204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunoregulatory role of dopamine: an update.
    Sarkar C; Basu B; Chakroborty D; Dasgupta PS; Basu S
    Brain Behav Immun; 2010 May; 24(4):525-8. PubMed ID: 19896530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.